IRIS
MASSIMINO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.701
EU - Europa 1.351
AS - Asia 307
AF - Africa 239
OC - Oceania 2
SA - Sud America 1
Totale 3.601
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.615
IT - Italia 475
IE - Irlanda 333
UA - Ucraina 219
CN - Cina 215
CI - Costa d'Avorio 154
DE - Germania 99
CA - Canada 86
SN - Senegal 73
RU - Federazione Russa 63
VN - Vietnam 36
BE - Belgio 34
GB - Regno Unito 25
SE - Svezia 24
IN - India 16
NL - Olanda 16
FR - Francia 13
CH - Svizzera 12
NG - Nigeria 12
UZ - Uzbekistan 9
GR - Grecia 8
PL - Polonia 7
IR - Iran 6
SG - Singapore 6
AT - Austria 5
BG - Bulgaria 4
TR - Turchia 4
ES - Italia 3
FI - Finlandia 3
HK - Hong Kong 3
LB - Libano 3
NO - Norvegia 3
AU - Australia 2
JP - Giappone 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BH - Bahrain 1
BR - Brasile 1
CZ - Repubblica Ceca 1
IL - Israele 1
PK - Pakistan 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 3.601
Salva come PNG Salva come JPEG
Città #
Chandler 443
Dublin 333
Jacksonville 222
Abidjan 154
Catania 148
Cambridge 94
Lawrence 92
Andover 88
Ashburn 85
Nanjing 82
Dakar 73
Grafing 65
Toronto 60
Des Moines 49
San Mateo 44
Wilmington 44
Dong Ket 27
Boardman 26
Palermo 23
Brussels 21
Ottawa 20
Shenyang 18
Hebei 17
Nanchang 17
Jiaxing 16
Falls Church 15
Saint Petersburg 15
Milan 14
Abuja 12
Bremen 12
Santa Venerina 12
Seattle 12
Changsha 11
Hanoi 9
Izegem 9
Messina 9
Pune 9
Rotterdam 9
Tianjin 9
Los Angeles 8
Redmond 8
Rome 8
Beijing 7
Aci Catena 6
Acireale 6
Leawood 6
Portland 6
Washington 6
Fantina 5
Giardini-Naxos 5
Hanover 5
Milazzo 5
Moscow 5
Norwalk 5
Ardabil 4
Augusta 4
Edinburgh 4
Grammichele 4
Houston 4
Liberty Lake 4
Paternò 4
Siracusa 4
Temse 4
Zafferana Etnea 4
Ann Arbor 3
Arcugnano 3
Bedford 3
Catanzaro 3
Cosenza 3
Den Haag 3
Fairfield 3
Frankfurt Am Main 3
Hangzhou 3
Lappeenranta 3
Montreal 3
Nicolosi 3
Ningbo 3
Oslo 3
Padova 3
Quintano 3
Redwood City 3
Rometta 3
Torregrotta 3
Verona 3
Woodbridge 3
Zhengzhou 3
Aci Sant'Antonio 2
Alessandria 2
Bari 2
Boydton 2
Calatabiano 2
Fiumefreddo Di Sicilia 2
Florence 2
Frankfurt am Main 2
Gravina di Catania 2
Guangzhou 2
Jinan 2
Kunming 2
London 2
Madrid 2
Totale 2.643
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 83
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 67
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 63
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 61
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 61
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 57
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 57
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 57
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 55
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 55
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 53
A novel and selective sigma-1/2 receptor ligand (PO680C): Binding properties and expression of tissue transglutaminase 53
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 52
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 51
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 51
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 51
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 51
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 51
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 51
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 50
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 50
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 50
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 50
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 49
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 49
Uncommon long-term survival in a patient with chronic myeloid leukemia 48
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 47
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 47
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 47
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 47
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 46
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 46
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 46
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 45
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 45
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 44
New insights in thyroid cancer and p53 family proteins 43
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 42
A novel and selective σ1/2 receptor ligand (PO680C): binding properties and expression of tissue transglutaminase 42
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 42
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 42
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 41
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 41
UNFAVOURABLE OUTCOME OF CML PATIENTS CARRYING COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS TREATED WITH TYROSINE KINASE INHIBITORS 40
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 39
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 39
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 39
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 39
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 38
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 38
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 38
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 38
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 37
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 37
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 36
Opportunities and challenges of liquid biopsy in thyroid cancer 36
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 35
Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report 35
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 35
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 33
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 33
Comparative proteomic analysis of insulin receptor isoform A and B signaling 32
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 32
EFFICACY OF IMATINIB MESYLATE ON CHRONIC PHASE CML PATIENTS ACCRUED IN THE SCREEN MULTICENTER STUDY: INTERIM REPORT ON THE FIRST 193 CASES 32
SYNTHESIS OF BNIT AN ISOTHIOCYANATE DERIVATIVE OF N-BENZYL-NORMETAZOCINE AS ACYLANT AGENT FOR σ1 RECEPTOR 32
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 32
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 31
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines 31
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 31
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 31
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 31
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 31
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 30
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 30
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 29
THE SCREEN PROJECT: A CML DATA REGISTRY IN SICILY AND CALABRIA 29
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 29
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 29
Computational and biological characterization of nuclear import/export signals of the human BCR protein 28
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 28
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 28
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 27
IRF5 promotes the proliferation of human thyroid cancer cells. 27
HIGH BCR-ABL EXPRESSION LEVELS AT DIAGNOSIS MAY PREDICT UNFAVOURABLE CML RESPONSES TO IMATINIB THERAPY 25
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 24
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor 23
RAPID RESPONSE TO DASATINIB IN A CML BLAST CRISIS PATIENT THAT SUBSEQUENTLY DEVELOPED SEQUENTIAL BCR-ABL MUTATIONS CAUSING MULTI-DRUG RESISTANCE: A CASE REPORT 23
Molecular dynamics simulations reveal the role of five BCR-ABL kinase domain critical residues in TKIS binding 22
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 21
SINTESI E VALUTAZIONE FARMACOLOGICA DI DERIVATI METIL 2-[(4-BENZILPIPERIDIN-1-IL)METIL]-1-FENIL-CICLOPROPANCARBOSSILATO COME LIGANDI SIGMA AD ALTA AFFINITÀ 21
TOWARDS A NEED IN OPTIMIZING CML MANAGEMENT IN SUBOPTIMAL RESPONDERS: DATA FROM THE SCREEN REGISTRY 20
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 20
HIGH DOSE IMATINIB TO ACHIEVE MOLECULAR RESPONSES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LATE CHRONIC PHASE AND COMPLETE CYTOGENETIC RESPONSE: IS IT WORTHWHILE? 19
Computational and Experimental Characterization of Critical Amino Acid Residues in the BCR-ABL Kinase Domain Explaining Imatinib Resistance in Patients with Chronic Myeloid Leukemia 18
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib 18
HIGH BCR-ABL EXPRESSION LEVELS AT DIAGNOSIS MAY PREDICT UNFAVOURABLE CML RESPONSES TO IMATINIB THERAPY 17
Totale 3.775
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201912 0 0 0 0 0 0 0 0 0 0 2 10
2019/2020428 141 16 37 11 38 9 21 14 39 6 45 51
2020/2021545 19 38 49 11 130 16 51 3 108 4 68 48
2021/2022693 55 98 15 9 113 13 104 27 53 14 35 157
2022/20231.376 107 102 43 153 91 215 19 264 289 11 50 32
2023/2024544 57 107 30 37 32 184 11 44 7 35 0 0
Totale 3.775